Evedrolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Eng J. Med, Dec 2011
Baselga, J., et al.
http://www.nejm.org/doi/full/10.1056/NEJMoa1109653#t=article
Endocrine therapy is the cornerstone of treatment for patients with hormone-receptor (HR)–positive advanced breast cancer. In postmenopausal patients, aromatase inhibitors (e.g., letrozole and anastrozole) have become the treatment of choice in first-line therapy. Unfortunately, not all patients have a response to first-line endocrine therapy (primary or de novo resistance), and even patients who have a response will eventually relapse (acquired resistance).
